U.S. stock futures edge higher; earnings season continues
Investing.com - TD Cowen raised its price target on BioNTech (NASDAQ:BNTX) to $120.00 from $110.00 on Monday, while maintaining a Hold rating on the stock. According to InvestingPro data, analyst targets for BioNTech range from $112 to $172, with the company maintaining a robust financial position, holding more cash than debt on its balance sheet.
The firm cited BioNTech’s second-quarter Comirnaty sales of €153 million, which exceeded consensus estimates of €85 million and TD Cowen’s own projection of €70 million.
BioNTech reaffirmed its fiscal year 2025 guidance, according to TD Cowen’s research note.
The company has several upcoming data readouts scheduled, including results for BNT327 from global Phase 2 dose optimization trials in SCLC/TNBC in the second half of 2025, BNT111 in R/R melanoma at ESMO, and BNT122 in 1L melanoma at ESMO and adjuvant CRC in late 2025 or early 2026.
TD Cowen indicated it has increased estimates for BNT327 and adjusted its model to account for BioNTech’s collaboration with Bristol Myers (NYSE:BMY) Squibb, contributing to the $10 increase in the price target.
In other recent news, BioNTech reported its second-quarter 2025 financial results, revealing a significant revenue increase. The company achieved revenues of €260.8 million, which more than doubled compared to the previous year and surpassed analyst estimates of €137.9 million. Despite this revenue growth, BioNTech posted a net loss of €386.6 million, translating to a loss of -€1.60 per share, slightly worse than the anticipated -€1.41 per share. In addition to the earnings report, BioNTech’s outlook was bolstered by a deal with Bristol Myers. Clear Street responded to these developments by raising its price target for BioNTech from $181 to $185 while maintaining a Buy rating. These recent events have contributed to a positive outlook for the company’s future.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.